Compare Direxion Daily FTSE China Bull 3x Shares (YINN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily FTSE China Bull 3x Shares vs Zoetis Inc — how do they compare? Direxion Daily FTSE China Bull 3x Shares trades at $27.89, while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Direxion Daily FTSE China Bull 3x Shares is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| YINN | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $56.62 | $156.76 |
52-Week Low | $21.45 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $28.89, up 7.84% with strong bullish technical signals from moving averages and ADX indicators. The leveraged ETF structure amplifies exposure to Chinese equities, which face mixed sentiment amid US-China tech tensions but show resilience through AI and semiconductor sector strength. Recent news highlights China's $295 billion AI infrastructure plan and export growth exceeding expectations.
Outlook remains cautiously optimistic given China's tech sector momentum and infrastructure investments, though leveraged ETF risks and geopolitical tensions pose significant volatility. The fund's 3x daily leverage requires careful risk management amid ongoing regulatory scrutiny and market uncertainty.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
